Regeneron Stock Soars 13%, Adding $11 Billion In Value As Sanofi Payments Surge
Shares hit a 52-week high after quarterly revenue rose 36.3% and executives called a new liver drug "game-changing."
Regeneron Pharmaceuticals shares climbed 13.10% to $926.03 in Friday trading, as of 9:55 a.m. ET, adding $11 billion in market value and hitting a new 52-week high. The move came after third-quarter results showed Sanofi collaboration revenue jumping 68%.
Sanofi money drives the quarter
Adjusted earnings came in at $20.07 per share on revenue of $5.1 billion, up 36.3% from a year earlier, the company reported. Net income for the quarter ended September 30 was $1.9 billion.
The quarterly filing also showed a higher 2026 research budget and lower sales-cost guidance. Sanofi records global sales of Dupixent, the allergy and inflammation drug it shares with Regeneron, according to the company's annual report.
The stock was on pace for its biggest one-day gain in at least 275 trading sessions, since Sept. 26, 2025.
A liver drug called game-changing
On the earnings call, executives described a new liver-disease drug as "game-changing" but held back details. They said they will discuss it at an investor roundtable on November 10.
Regeneron is a biotechnology company that develops, makes and sells medicines for serious diseases. Its marketed products include Eylea HD and Eylea for eye disease, Libtayo for cancer and Praluent for cholesterol-related conditions.
A laggard turns leader
Before the jump, the stock was up about 6% year to date as of Thursday's close, trailing the S&P 500, which was up about 13% over the same span. Friday's surge lifts it to a fresh 52-week high.
The next date that matters is the November 10 roundtable, where Regeneron executives said they would detail the liver drug.
Sources
- Regeneron stock gains on Q3 beat (REGN:NASDAQ) | Seeking Alpha — seekingalpha.com
- Regeneron, Sanofi Surge As Dupixent Wallops Sales Forecasts | Investor's Business Daily — investors.com
- Regeneron: Q3 Earnings Snapshot — Associated Press
- Regeneron (REGN) Q3 Earnings and Revenues Beat Estimates — Yahoo Finance
- Regeneron Pharmaceuticals Non-GAAP EPS of $20.07 beats by $3.82, revenue of $5.1B beats by $540M (NASDAQ:REGN) | Seeking Alpha — seekingalpha.com
- The company's filing (Regeneron Pharmaceuticals) — SEC filing
- Regeneron Pharmaceuticals — Form 10-Q for the quarter ended 2026-09-30 (quarterly results) — SEC EDGAR
More on Regeneron Pharmaceuticals
- Regeneron Settles Its Sanofi Lawsuit, Then Adds Four Antibodies To The Alliance For $1.0 Billion Up Front
- Regeneron Revenue Climbs 36% To $5.1 Billion As Sanofi Profit Share Surges, Plus A $1 Billion Up-Front Deal
- Sanofi Pays Regeneron $1.0 Billion Upfront For Four Antibodies, With Up To $7.0 Billion More In Milestones